%PDF-1.4
%
53 0 obj
<>
endobj
50 0 obj
<>
endobj
111 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T18:01:33Z
2024-03-28T02:09:26-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T02:09:26-07:00
application/pdf
Heather
2002-129.nov02
uuid:c3a16267-1dd1-11b2-0a00-6b0927edca00
uuid:c3a16269-1dd1-11b2-0a00-380000000000
endstream
endobj
39 0 obj
<>
endobj
40 0 obj
<>
endobj
54 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
16 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
19 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
22 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
145 0 obj
[149 0 R]
endobj
146 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
427 777 130 -27 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 420.9531 35.9844 Tm
[(The Journal of Rheumatology 2002; 29:1)74 (1)]TJ
0 Tw -45.8691 -0.0313 Td
(2358)Tj
ET
0 0 0 0 scn
/GS0 gs
103.38 59.75 407.5 -10.83 re
f*
0.5 w
103.38 59.75 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.29739 Tw 10 0 0 10 54 713.1616 Tm
[(cians\222)-473.4 (than to patients\222)-473.5 (perceptions of change and why)]TJ
-0.00011 Tc 0.26311 Tw 0 -1.2 TD
(SLAM-R appears to be more responsive than SLEDAI.)Tj
0 Tc 0.12421 Tw T*
(These results highlight the need for better communication)Tj
0.0601 Tw T*
(between patients and physicians, and for inclusion of more)Tj
0.037 Tw T*
(patient-reported manifestations in instruments if they are to)Tj
0.1122 Tw T*
(respond better to patient assessments of change in disease)Tj
0 Tw T*
[(activity)64.9 (.)]TJ
/TT2 1 Tf
-0.00011 Tc 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/TT1 1 Tf
0 Tc -0.02499 Tw 8 0 0 8 54 607.1616 Tm
[(The authors thank Roxane du Ber)17.8 (ger and Marielle Olivier for their valuable)]TJ
-0.00011 Tc 0.02499 Tw 0 -1.25 TD
(assistance with SAS.)Tj
/TT2 1 Tf
-0.0002 Tc 0 Tw 10 0 0 10 54 573.1616 Tm
(APPENDIX)Tj
/TT1 1 Tf
0 Tc 0.10899 Tw 8 0 0 8 54 563.1616 Tm
(Investigators and co-investigators in the Study of Methotrexate in Lupus\
)Tj
-0.00011 Tc 0.02499 Tw T*
(Erythematosus \(SMILE\).)Tj
0.0148 Tw T*
[(Principal Investigator: P)110.7 (.R. Fortin, MD, MPH, University Health Network,)]TJ
0.0484 Tw T*
[(T)69.7 (oronto, Ontario \(formerly at McGill University Health Centre, Montreal,\
)]TJ
0 Tw T*
(Quebec\).)Tj
0.214 Tw T*
(Co-Investigators and Institutions \(listed in order of number of patient\
s)Tj
0.0925 Tw T*
[(entered into the study\): M. )54.9 (Abrahamowicz, PhD; D. Ferland, RN, BScN;)]TJ
0.02859 Tw T*
(A.E. Clarke, MD, MSc; J. Penrod, PhD, McGill University Health Centre,)Tj
-0.0074 Tw T*
(Montreal, Quebec. D. Lacaille, MD, MHSc; J.M. Esdaile, MD, MPH; H.B.)Tj
-0.0072 Tw T*
[(Stein, MD, )54.9 (Arthritis Research Centre of Canada, )17.8 (V)111 (ancouver)39.7 (, BC. D. Smith,)]TJ
0.21111 Tw T*
[(MD, Ottawa Hospital, General Campus, Ottawa, Ontario. M. Zummer)39.7 (,)]TJ
0.0486 Tw T*
[(MD; J-P)110.8 (. Mathieu, MD; L. Duchesne, MD; S. Mercille, MD; P)110.8 (.)-0.1 ( Dagenais,)]TJ
0.0527 Tw T*
(MD, PhD, H\364pital Maisonneuve-Rosemont, Montreal, Quebec. J.E. Pope,)Tj
0.1329 Tw T*
[(MD, MPH, St. Joseph\222)54.8 (s Hospital, London, Ontario \(formerly at )17.7 (V)60 (ictoria)]TJ
0.14169 Tw T*
[(Hospital, London, Ontario\). S. Edworthy)64.8 (, MD; S. Barr)39.7 (, MD; G. Morris,)]TJ
0 Tc 0.0614 Tw T*
[(MD, Calgary Health Sciences Centre, Calgary)65 (, )54.8 (Alberta. M. Starr)39.8 (, MD, St.)]TJ
-0.0199 Tw T*
[(Mary\222)54.9 (s Hospital, Montreal, Quebec. )17.8 (V)129.2 (. Bykerk, MD, Mount Sinai Hospital,)]TJ
0.01379 Tc 0.3611 Tw T*
[(T)69.8 (oronto, Ontario \(formerly at Credit )17.6 (V)111 (alley Hospital, Mississauga,)]TJ
-0.00011 Tc 0.12199 Tw T*
[(Ontario\). S. Bernatsky)64.9 (, MD; J. Canvin, MD; H.S. El-Gabalawy)64.9 (, MD; C.)]TJ
0 Tc 0.0016 Tw T*
[(Peschken, MD, )17.7 (W)39.8 (innipeg Health Sciences Centre, )17.7 (W)39.8 (innipeg, Manitoba. )54.8 (A.)]TJ
0.00191 Tc 0.373 Tw T*
[(Cividino, MD, McMaster)19.7 (-Chedoke Hospital, Hamilton, Ontario. J-L.)]TJ
0 Tc 0.22301 Tw T*
[(Sen\351cal, MD; J-P)110.8 (. Raynauld, MD; E. Rich, MD, H\364pital Notre-Dame,)]TJ
-0.00011 Tc 0.2662 Tw T*
[(Montreal, Quebec. C. Kirk Osterland, MD; C.A. )36.8 (Y)100 (eadon, MD, Royal)]TJ
0 Tc 0.1404 Tw T*
[(V)60.1 (ictoria Hospital, Montreal, Quebec. )55 (A. Beaulieu, MD; S. Carette, MD,)]TJ
0.07651 Tw T*
[(Centre Hospitalier de l\222Universit\351 Laval, Quebec City)65 (, Quebec. G. Boire,)]TJ
-0.00011 Tc 0.0639 Tw T*
(MD, MSc, Centre Hospitalier de l\222Universit\351 de Sherbrooke, Sherbro\
oke,)Tj
-0.02969 Tw T*
(Quebec. SMILE research assistants: R. Morrison, RN, MSN; E.S. Clark; K.)Tj
-0.0127 Tw T*
[(Rangno, RN, )54.9 (Arthritis Research Centre of Canada, )17.7 (V)111 (ancouver)39.7 (, BC. P)110.7 (.)-0.1 ( Dale,)]TJ
-0.0051 Tw T*
[(Ottawa General Hospital, Ottawa, Ontario. D.L. Fenlon, BScN; )17.8 (W)91.7 (. Curran;)]TJ
0 Tc 0.11481 Tw T*
[(L. Bere, RN, )17.8 (V)60.1 (ictoria Hospital, London, Ontario. R. )17.8 (T)69.8 (alavera; B. Green,)]TJ
-0.0032 Tw T*
[(BN, BScN; E. )17.8 (T)69.8 (eixeira, RN, BN, Calgary Health Sciences Centre, Calgary)65 (,)]TJ
-0.00011 Tc 0.037 Tw T*
[(Alberta. J. O\222Farrell, RN, Credit )17.8 (V)111 (alley Hospital, Mississauga, Ontario. S.)]TJ
0 Tc 0.0071 Tw T*
[(W)79.8 (ood, RN; )54.9 (A. Huggard, RN, )17.7 (W)39.8 (innipeg Health Sciences Centre, )17.7 (W)39.8 (innipeg,)]TJ
0.0049 Tc 0.37 Tw T*
[(Manitoba. J. Zahavich, RN, McMaster)19.8 (-Chedoke Hospital, Hamilton,)]TJ
-0.00011 Tc 0.0817 Tw T*
(Ontario. M. Prave, RN, Centre Hospitalier de l\222Universit\351 Laval, Q\
uebec)Tj
0 Tc 0.02499 Tw T*
[(City)64.9 (, Quebec.)]TJ
/TT2 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 318 713.1616 Tm
(REFERENCES)Tj
/TT1 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 325 703.1616 Tm
[(1.)-925 (Hochber)17.8 (g M. )17.7 (The epidemiology of systemic lupus)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(erythematosus. In: )17.7 (W)79.7 (allace DJ, Hann BH, editors. Dubois\222)-201.1 (lupus)]TJ
0 Tc T*
(erythematosus. Philadelphia: Lea & Febiger; 1993:49-57.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-925.1 (Liang MH, Stern S, Esdaile JM. Systemic lupus erythematosus)]TJ
0 Tc 1.675 -1.25 Td
[(activity)65 (. )54.9 (An operational definition. Rheum Dis Clin North )54.9 (Am)]TJ
0 Tw T*
(1988;14:57-66.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-925.1 (Liang MH, Socher SA, Larson MG, Schur PH. Reliability and)]TJ
1.675 -1.25 Td
(validity of six systems for the clinical assessment of disease)Tj
0 Tc T*
[(activity in systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
[(1989;32:1)36.9 (107-18.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-925.1 (Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.)]TJ
0 Tc 1.675 -1.25 Td
[(Derivation of the SLEDAI. )54.8 (A)-219.8 (disease activity index for lupus)]TJ
T*
[(patients. )17.8 (The Committee on Prognosis Studies in SLE. )54.9 (Arthritis)]TJ
T*
(Rheum 1992;35:630-40.)Tj
-1.675 -1.25 Td
[(5.)-925 (Petri M, Hellmann D, Hochber)17.8 (g M. )17.7 (V)111.1 (alidity and reliability of lupus)]TJ
1.675 -1.25 Td
(activity measures in the routine clinic setting. J Rheumatol)Tj
0 Tw T*
(1992;19:53-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-925.1 (W)79.7 (ard MM, Marx )54.8 (AS, Barry NN. Comparison of the validity and)]TJ
0 Tc 1.675 -1.25 Td
(sensitivity to change of 5 activity indices in systemic lupus)Tj
T*
(erythematosus. J Rheumatol 2000;27:664-70.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-925.1 (Fortin PR, )54.8 (Abrahamowicz M, Clarke )54.8 (AE, et al. Do lupus disease)]TJ
0 Tc 1.675 -1.25 Td
(activity measures detect clinically important change? J Rheumatol)Tj
0 Tw T*
(2000;27:1421-8.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-925.1 (Chang E, )54.8 (Abrahamowicz M, Ferland D, Fortin P)110.7 (. Comparison of)]TJ
0 Tc 1.675 -1.25 Td
(the responsiveness of lupus disease activity measures to changes in)Tj
T*
(systemic lupus erythematosus activity relevant to patients and)Tj
T*
(physicians. J Clin Epidemiol 2002;55:488-97.)Tj
-1.675 -1.25 Td
[(9.)-925 (Gladman D, Ginzler E, Goldsmith C, et al. )17.8 (The development and)]TJ
1.675 -1.25 Td
(initial validation of the Systemic Lupus International Collaborating)Tj
T*
(Clinics/American College of Rheumatology damage index for)Tj
T*
[(systemic lupus erythematosus. )54.8 (Arthritis Rheum 1996;39:363-9.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(10.)-925.1 (Medlog Systems. Incline )17.7 (V)60 (illage, NV)73.9 (: Medlog Systems; 1995.)]TJ
0.0369 -1.25 Td
[(1)36.8 (1)-0.1 (.)-925.1 (SAS. Cary)64.8 (, NC: SAS Institute Inc.; 1999.)]TJ
0 Tc -0.0369 -1.25 Td
[(12.)-925 (Liang KY)128.9 (, Zeger SL. Longitudinal data analysis using )]TJ
2.175 -1.25 Td
(generalized linear models. Biometrika 1986;73:13-22.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-925.1 (Jennrich RI, Schluchter MD. Unbalanced repeated-measures)]TJ
0 Tc 2.175 -1.25 Td
(models with structured covariance matrices. Biometrics)Tj
0 Tw T*
(1986;42:805-20.)Tj
0.0249 Tw -2.175 -1.25 Td
[(14.)-925 (Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to)]TJ
2.175 -1.25 Td
(change of 3 systemic lupus erythematosus disease activity indices:)Tj
T*
(international validation. J Rheumatol 1994;21:1468-71.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-925.1 (Brunner HI, Feldman BM, Bombardier C, Silverman ED.)]TJ
2.175 -1.25 Td
[(Sensitivity of the Systemic Lupus Erythematosus Disease )54.8 (Activity)]TJ
T*
[(Index, British Isles Lupus )54.8 (Assessment Group Index, and Systemic)]TJ
0 Tc T*
[(Lupus )54.9 (Activity Measure in the evaluation of clinical change in)]TJ
T*
[(childhood-onset systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1999;42:1354-60.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
92 0 obj
<>
endobj
116 0 obj
<>
endobj
56 0 obj
<>
endobj
66 0 obj
<>
endobj
26 0 obj
<>
endobj
32 0 obj
<>
endobj
33 0 obj
<>stream
HdVpTs͋Ѡ,1$^XG.